Why Meds in Development?

04.22.13 | By

PhRMA explores the potential medicines in the biopharmaceutical pipeline on a regular basis through our Medicines in Development reports and other related efforts. Simply put, the pipeline is the foundation of PhRMA member companies.

Reviving the Antibiotic Pipeline

04.22.13 | By

A new report on the antibiotic pipeline is causing renewed concern given the emergence of antibiotic-resistant “superbugs” with high mortality rates. 

Antibiotic-Resistance Poses Grave Danger

Researching and Racing for a Blood Cancer Cure

04.22.13 | By

A passion to help others. Above all else, this is the prevailing quality inherent in the biopharmaceutical sector and in partners throughout the health care field. We help people live longer, better lives. We see it every day in the work we do and the people with whom we interact. This week, PhRMA is excited to be a part of two activities that epitomize this galvanizing mindset.

World Orphan Drug Congress Explores Policies Impacting Development of Rare Disease Therapies

04.19.13 | By

While most of my colleagues were in San Diego last week for the PhRMA Annual Meeting, I attended the World Orphan Drug Congress in DC.  Industry leaders such as Freda Lewis-Hall of Pfizer, officials from the Food and Drug Administration (FDA) and National Institutes of Health (NIH) and representatives

2013 Award In Excellence in Pharmacology/Toxicology

04.19.13 | By

Every year, the PhRMA Foundation grants Awards in Excellence to past awardees who are dramatic, living proof that the Foundation program works and makes a difference. These awards are given to scientists who received a Foundation grant at the outset of their careers and went on to distinguish themselves through their scientific and/or academic achievements. We had an opportunity to speak with this year's recipient of the Award in Excellence in Pharmacology/Toxicology, William B.

Clinical Trial Event in Maine Unites Patients, Governor and Industry in Fight Against Disease

04.19.13 | By

The Research In Your Backyard (RIYB) event was a bright spot of hope amid an otherwise overcast day in Augusta, and PhRMA President and CEO (and longtime Maine resident) John Castellani spoke to his hometown crowd about the impact of clinical trials in Maine. With more than 560 clinical trials that have been conducted or are still occurring in the state in the past 13 years, the RIYB program provides an important message of hope to both patients and the state's economy.

PhRMA Reacts to Part D Rebates Legislation

04.16.13 | By

Today there was legislation introduced by several members of Congress that would impose mandatory government price controls in the form of rebates in Medicare Part D. We’ve talked a lot on the Catalyst about the success of Medicare Part D, both for seniors and taxpayers, and this proposed policy would unravel much of that success.

PhRMA Statement on Medicare Drug Savings Act of 2013

WASHINGTON, D.C. (April 16, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett today issued the following statement:

#PhRMA13 Closes With Focus on Patients and Challenges That Lie Ahead

A strong finish to #PhRMA13 today drove home the message that for patients, there is no greater source of hope than the continued medical innovation that leads to new treatments and further, new hope. 

Rx Minute: Higher Copays Slow Start of Treatment for Patients with Chronic Conditions

A 2009 study by RAND researchers, sponsored by the Agency for Healthcare Research and Quality (AHRQ) and published in the Archives of Internal Medicine, found that with higher copayments, patients who are newly diagnosed with chronic diseases are slower to begin drug treatments. The authors state that out of pocket costs “may prevent patients from initiating medically necessary care.”


Subscribe to RSS - Opinion